At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 327 enrolled
Drug / intervention
Lurasidone 40 mg +2 moredrug
Likely dose
Lurasidone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Lurasidone 40 mg, Lurasidone 80 mg, and 1 other intervention for Schizophrenia. Completed, enrolled 327 participants across 90 sites in 17 countries.
Detailed Summary
Efficacy and Safety study of Lurasidone in pediatric patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesBelgium, Bulgaria, Colombia, France, Hungary, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Romania, Russia, South Korea, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartAug 2013
Primary CompletionDec 2015
TodayJul 2026
First PostedJul 30, 2013
Enrollment StartAug 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.9 years ago
Interventions
Lurasidone 40 mgdrug
Lurasidone 40 mg once daily
Lurasidone 80 mgdrug
Lurasidone 80 mg once daily
Placebo 40 or 80 mgdrug
Placebo 40 or 80 mg once daily